NCT06398730已完成1 期
A Phase 1, Single-Center, Open-Label, Single-Arm, Dose-Escalation, Positron Emission Tomography Study to Assess the Safety and Tolerability, Immunogenicity, Pharmacokinetics, Dosimetry and Biodistribution Following GEH200521 (18F) Injection Co-Administered With GEH200520 Injection in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 22
- 试验地点
- 1
- 主要终点
- Incidence of all TEAEs
研究概览
简要总结
This is a Phase 1, single-center, open-label, single-arm, dose-escalation positron emission tomography study to assess the safety and tolerability, immunogenicity, Pharmacokinetics, dosimetry, and biodistribution after GEH200521 (18F) Injection is co-administered with GEH200520 Injection in healthy volunteers.
The estimated study duration for each subject is approximately 28 days in part A and 34 days in part B.
The primary study objective is to evaluate the safety and tolerability of the IMPs, the selected mass doses of GEH200520 Injection co-administered with a fixed dose of GEH200521 (18F) Injection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The subject is able and willing to comply with all study procedures as described in the protocol, and has read, signed, and dated an informed consent form prior to any study procedures being performed.
- •The subject is male or female ≥18 years of age.
- •The subject has a body mass index (BMI) ≥18 and ≤35 kg/m
- •The subject has no history of chronic medical illness or symptoms of active illness per Investigator's assessment.
- •The subject has no clinically significant deviation from normal ranges in physical examination, ECG, and clinical laboratory parameters.
- •Female and male contraception methods.
排除标准
- •Subject is using prescribed and/or non-prescribed medication which in the Investigator's opinion might impact subject safety or the study results.
- •Subject has a known or suspected allergy to IMP and/or IMP ingredients.
- •Subject has had a surgery within 8 weeks prior to enrollment or a surgery is scheduled during the study.
- •Subject has been enrolled in this or another interventional clinical study within the 30 days before screening for this study or is actively participating in another clinical study with IMP(s).
- •Subject has been enrolled in another clinical study with radiation or exposed to radiation due to medical practice, which in the Investigator's opinion might impact subject safety or the study results.
- •Subject is pregnant, planning to become pregnant, or is lactating.
- •Creatinine and liver function laboratory values higher than 1.5x upper limit ranges per local site clinical practice.
研究组 & 干预措施
A non-radiolabeled GEH200520 - 8 mg
Experimental
干预措施: Static - PET/CT scan (Diagnostic Test)
A non-radiolabeled GEH200520 - 10 mg
Experimental
干预措施: GEH200520 Injection and GEH200521 (18F) Injection (Drug)
A non-radiolabeled GEH200520 - 1 mg
Experimental
干预措施: GEH200520 Injection and GEH200521 (18F) Injection (Drug)
A non-radiolabeled GEH200520 - 1 mg
Experimental
干预措施: Static - PET/CT scan (Diagnostic Test)
A non-radiolabeled GEH200520 - 10 mg
Experimental
干预措施: Static - PET/CT scan (Diagnostic Test)
A non-radiolabeled GEH200520 - 12 mg or 15 mg
Experimental
干预措施: GEH200520 Injection and GEH200521 (18F) Injection (Drug)
A non-radiolabeled GEH200520 - 12 mg or 15 mg
Experimental
干预措施: Static - PET/CT scan (Diagnostic Test)
A non-radiolabeled GEH200520 - 2 mg
Experimental
干预措施: GEH200520 Injection and GEH200521 (18F) Injection (Drug)
A non-radiolabeled GEH200520 - 2 mg
Experimental
干预措施: Static - PET/CT scan (Diagnostic Test)
A non-radiolabeled GEH200520 - 4 mg
Experimental
干预措施: GEH200520 Injection and GEH200521 (18F) Injection (Drug)
A non-radiolabeled GEH200520 - 4 mg
Experimental
干预措施: Static - PET/CT scan (Diagnostic Test)
A non-radiolabeled GEH200520 - 6 mg
Experimental
干预措施: GEH200520 Injection and GEH200521 (18F) Injection (Drug)
A non-radiolabeled GEH200520 - 6 mg
Experimental
干预措施: Static - PET/CT scan (Diagnostic Test)
A non-radiolabeled GEH200520 - 8 mg
Experimental
干预措施: GEH200520 Injection and GEH200521 (18F) Injection (Drug)
结局指标
主要结局
Incidence of all TEAEs
时间窗: 7 days
Incidence of all grading of TEAEs per National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 based on the causality to the IMPs.
次要结局
- Radiation dosimetry and biodistribution of GEH200521 (18F) Injection after the GEH200520 Injection mass doses.(7 days)
- Optimal imaging window post-GEH200521 (18F) Injection after the GEH200520 Injection mass doses.(7 days)
- Mass dose of GEH200520 Injection followed by a fixed dose of GEH200521 (18F) Injection to achieve a diagnostic positron emission tomography (PET) image quality.(7 days)
- Pharmacokinetic property of the area under the curve (AUC) of total protein following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection.(7 days)
- Pharmacokinetic property of Cmax of total protein following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection.(7 days)
- Pharmacokinetic property of clearance (CL) of total protein following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection.(7 days)
- Pharmacokinetic property volume of distribution (V) of total protein following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection.(7 days)
- To characterise the pharmacokinetic property of the elimination half-life (t1/2) of total protein following administration of different GEH200520 Injection mass doses with a fixed dose of GEH200521 (18F) Injection.(7 days)
- Collection of the incidence, severity, changes between visits for AEs/SAEs/AESIs.(7 days)
- Proportion of subjects with clinically significant abnormalities detected during physical examination status by system organs following administration of GEH200520 and GEH200521 (18F).(7 days)
- Proportion of subjects with clinically significant abnormalities detected for serum biochemistry test results following administration of GEH200520 and GEH200521 (18F).(7 days)
- Proportion of subjects with clinically significant abnormalities detected for haematology test results following administration of GEH200520 and GEH200521 (18F).(7 days)
- Proportion of subjects with clinically significant abnormalities detected for beats per minute following administration of GEH200520 and GEH200521 (18F).(7 days)
- Changes in systolic and diastolic blood pressure in mmHg following administration of GEH200520 and GEH200521 (18F).(7 days)
- Changes in temperature as degree F following administration of GEH200520 and GEH200521 (18F).(7 days)
- Proportion of subjects with clinically significant abnormalities detected during 12-lead electrocardiograms (ECGs) following administration of GEH200520 and GEH200521 (18F).(7 days)
- Incidence of treatment induced and treatment enhance anti drug antibody responses following administration of GEH200520 and GEH200521 (18F)(7 days)
- Test-retest imaging reliability of GEH200521 (18F) Injection co-administered with the selected mass dose of GEH200520 Injection, when administered on 2 different days(13 days)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A study of the effect of hydrogen peroxide foam in patients with bacterial vaginosisMedDRA version: 18.1Level: PTClassification code 10004055Term: Bacterial vaginosisSystem Organ Class: 10021881 - Infections and infestationsBacterial vaginosisEUCTR2015-003356-51-SEZelmic AB30
已完成
1 期
Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT01056029GenSpera, Inc.30
已完成
1 期
An open label, single arm, dose escalation phase 1 trial of PRI-724 in patients with HCV-induced cirrhosisHepatitis C virus-induced cirrhosisJPRN-UMIN000014395Tokyo metropolitan Komagome Hospital16
招募中
不适用
A Study on the Evaluation of the Safety and Effectiveness of Autologous activated lymphocyte Injection in Stage 4 Solid Cancer Patient.NeoplasmsKCT0006567Gsamhospital240
进行中（未招募）
1 期
Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (SMART)MedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersSpinal Muscular AtrophyEUCTR2020-005995-37-PTovartis Pharma AG24